GSK has developed a new propellant technology for inhaler devices that drastically reduces their use of greenhouse gases, which perhaps surprisingly account for nearly half (49%) of the group’s ...

Wockhardt will deepen its novel antibiotics pipeline over the next five years and focus on building a biosimilar business for ...

Several previous studies have suggested that shingles vaccinations might reduce dementia risk, but most could not exclude the ...

Aston Martins and Scotch whisky are likely to become more expensive in the US under Donald Trump.

If you deal with recurrent UTIs, a new FDA-approved antibiotic called Blujepa could offer another treatment option—especially ...

While acute hepatitis B infection is often resolved by the immune system, CHB occurs when the body's defences are unable to ...

Companies featuring in this week's round-up include The Education Network, Adderstone Group, AkzoNobel and Dulux, TT2 and the ...

GlaxoSmithKline is set to launch its COPD triple therapy in the US - and must now show that it can maximise sales of the drug with blockbuster potential. Approved yesterday by the FDA, Trelegy ...

CHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building ...

The most common causes of chronic cough include gastroesophageal reflux disease (GERD), asthma, and postnasal drip (also ...

RyCarma Therapeutics, Inc., a clinical-stage biotech company developing first-in-class small molecule therapeutics for cardiovascular and skeletal muscle diseases, has appointed Elizabeth Tarka, M.D., ...